Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)

Diffuse Parenchymal Lung Disease Clinical Trial

Official title: Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)

Status Recruiting

Clinical Trial Summary

The primary intention of this study is to determine the diagnostic performance of ultra-low-dose CT (ULDCT) in diagnosis and follow-up of diffuse parenchymal lung disease (DPLD). We hypothesize that inspiratory and expiratory chest ULDCT has comparable diagnostic yield to standard dose chest High-resolution computed tomography (HRCT) and utility for follow-up of patients with known DPLD. We will study this hypothesis through the following aims:

1. Determine whether inspiratory and expiratory ULDCT are comparable to HRCT in identifying mosaic attenuation due to air-trapping.

2. Determine whether ULDCT is as good as HRCT for follow-up of patients with established DPLD to identify disease progression.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Diffuse Parenchymal Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial

• NCT number: NCT04392726
• Study type: Observational
• Source: Sheba Medical Center
• Contact: Gal Varshavsky
• Phone: 972-3-5305997
• Email: Gal.Varshavsky@sheba.health.gov.il
• Status: Recruiting
• Start date: August 1, 2020
• Completion date: January 30, 2024